2016 is a turning point for orphan drugs and for neonatal screenings. While in Europe, orphan drug designation is being debated, in Italy, a scientifically inclusive environment is pushing for the finalisation of the law regarding extended neonatal screening. 100 patients, caregivers, future parents, students, researchers, health professionals, industrialists, institutional and communication representatives debated the complex issues that are affecting our quality of life. They played the newly updated kit-PlayDecide ORPHAN DRUGS in regions where training and community-building are keys to consolidate the cycle of early diagnosis and access to appropriate therapies. @UniamociOnlus